6.67 0.00 (0.00%)
After hours: 4:16PM EDT
|Bid||6.60 x 3100|
|Ask||6.74 x 1100|
|Day's Range||6.61 - 6.77|
|52 Week Range||1.86 - 7.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
In support of its growth strategy to become a global leader in Clean Beauty, Amyris (AMRS) has announced two executive appointments to ensure it can respond quickly to the surging consumer demand for its Clean Beauty skincare products from Biossance™, now the fastest selling skincare brand in North America. Caroline Hadfield has been promoted to President of Biossance, and is recognized for leading its launch and subsequent success with consumers looking for clean, non-toxic skincare that delivers superior performance. Formerly Senior Vice President of Personal Care at Amyris, Ms. Hadfield will continue to lead brand positioning, new product and category innovation and development, supply chain management and operations. A leading advocate for the introduction of Clean Beauty in the skincare market, she has successfully established Biossance as a leader in this rapidly growing sector of the market, delivering an outstanding range of Clean Beauty products that meet our No Compromise™ philosophy of safe, non-toxic ingredients that are efficacious and deliver superior performance.
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on AXTA sign up now at www.wallstequities.com/registration. WallStEquities.com has selected the following stocks for review: Aemetis Inc. (NASDAQ: AMTX), Amyris Inc. (NASDAQ: AMRS), Axalta Coating Systems Ltd (NYSE: AXTA), and Ecolab Inc. (NYSE: ECL).
Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, announces that it has closed on a $36 million term loan with Great American Capital Partners, LLC ("GACP"), a subsidiary of B. Riley Capital Management, LLC, an SEC Registered Investment Advisor and wholly-owned subsidiary of B. Riley Financial, Inc. Cash from the term loan will be used to pay off the company’s Stegodon and other short-term debt maturities. The term loan also includes an additional $35 million accordion credit facility that provides Amyris with another option for financing construction of its production facility, if necessary.
Amyris is disrupting markets by using the most advanced science and technology, including machine-learning and robotics to program yeast to create targeted molecules, at a lower cost and with sustainable supplies, resulting in sustainable methods of materials production. Amyris is the only company in the sector that has production capability at industrial scale, is evidenced by its clean manufacturing and commercialization of 15 products and its established supply agreements with market leaders across a range of business segments. Amyris is now expanding its production contract with ADL in order to provide additional, cost-effective manufacturing capability to meet the higher than expected demands from its partners.
Amyris, Inc. (AMRS), a leader in the development and production of sustainable, fermentation-derived ingredients in the markets of Health & Wellness, Clean Beauty and Flavors & Fragrances announces that it plans to partner with BGI, the world’s largest genomics company. The companies intend to apply their synthetic biology platforms in a new joint venture to discover, develop and commercialize human microbiome-targeting health and nutrition products in Greater China. The joint venture seeks to combine Amyris’s best-in-class science and technology with BGI’s gene sequencing expertise, data and analytics.
Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it has executed an agreement for a significant project consortium in Europe with the Universidade Católica Portuguesa (UCP) Porto Campus and AICEP Portugal Global (AICEP). UCP is a university system, including the leading biotech school in Portugal, and operates 15 research centers. AICEP is an independent public entity of the Government of Portugal, focused in encouraging the best foreign companies to invest in Portugal.
Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it is set to join the Russell Microcap® Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 25, according to a preliminary list of additions posted June 8. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell US Indexes primarily by objective, market-capitalization rankings and style attributes.
Amyris (AMRS) is one stock you should avoid as it has seen a significant price decline and is also seeing negative earnings estimate revisions.
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on AXTA sign up now at www.wallstequities.com/registration. Lined up for evaluation this morning are these four stocks: Aemetis Inc. (NASDAQ: AMTX), Amyris Inc. (NASDAQ: AMRS), Axalta Coating Systems Ltd (NYSE: AXTA), and Ecolab Inc. (NYSE: ECL).
|Initiated||Singular Research: to Buy||9/27/2016|
|Initiated||H.C. Wainwright: to Buy||11/10/2015|
|Initiated||Stifel Nicolaus: to Hold||5/28/2014|
|Upgrade||Cowen & Co.: to Market Perform||2/26/2014|
|Downgrade||Cowen & Co.: to Underperform||1/2/2014|
|Upgrade||Raymond James: to Market Perform||2/21/2013|
Sector: Basic Materials
Industry: Specialty Chemicals
Full Time Employees: 414
Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.